Incidence of serious gastrointestinal events among tildrakizumab‐treated patients with psoriasis: Letter to the Editor

Detalles Bibliográficos
Autores principales: Gooderham, M., Elewski, B.E., Pariser, D.M., Sofen, H., Mendelsohn, A.M., Rozzo, S.J., Li, Q.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850306/
https://www.ncbi.nlm.nih.gov/pubmed/31033068
http://dx.doi.org/10.1111/jdv.15643
_version_ 1783469396033798144
author Gooderham, M.
Elewski, B.E.
Pariser, D.M.
Sofen, H.
Mendelsohn, A.M.
Rozzo, S.J.
Li, Q.
author_facet Gooderham, M.
Elewski, B.E.
Pariser, D.M.
Sofen, H.
Mendelsohn, A.M.
Rozzo, S.J.
Li, Q.
author_sort Gooderham, M.
collection PubMed
description
format Online
Article
Text
id pubmed-6850306
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-68503062019-11-18 Incidence of serious gastrointestinal events among tildrakizumab‐treated patients with psoriasis: Letter to the Editor Gooderham, M. Elewski, B.E. Pariser, D.M. Sofen, H. Mendelsohn, A.M. Rozzo, S.J. Li, Q. J Eur Acad Dermatol Venereol Letters to the Editor John Wiley and Sons Inc. 2019-05-08 2019-10 /pmc/articles/PMC6850306/ /pubmed/31033068 http://dx.doi.org/10.1111/jdv.15643 Text en © 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Letters to the Editor
Gooderham, M.
Elewski, B.E.
Pariser, D.M.
Sofen, H.
Mendelsohn, A.M.
Rozzo, S.J.
Li, Q.
Incidence of serious gastrointestinal events among tildrakizumab‐treated patients with psoriasis: Letter to the Editor
title Incidence of serious gastrointestinal events among tildrakizumab‐treated patients with psoriasis: Letter to the Editor
title_full Incidence of serious gastrointestinal events among tildrakizumab‐treated patients with psoriasis: Letter to the Editor
title_fullStr Incidence of serious gastrointestinal events among tildrakizumab‐treated patients with psoriasis: Letter to the Editor
title_full_unstemmed Incidence of serious gastrointestinal events among tildrakizumab‐treated patients with psoriasis: Letter to the Editor
title_short Incidence of serious gastrointestinal events among tildrakizumab‐treated patients with psoriasis: Letter to the Editor
title_sort incidence of serious gastrointestinal events among tildrakizumab‐treated patients with psoriasis: letter to the editor
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850306/
https://www.ncbi.nlm.nih.gov/pubmed/31033068
http://dx.doi.org/10.1111/jdv.15643
work_keys_str_mv AT gooderhamm incidenceofseriousgastrointestinaleventsamongtildrakizumabtreatedpatientswithpsoriasislettertotheeditor
AT elewskibe incidenceofseriousgastrointestinaleventsamongtildrakizumabtreatedpatientswithpsoriasislettertotheeditor
AT pariserdm incidenceofseriousgastrointestinaleventsamongtildrakizumabtreatedpatientswithpsoriasislettertotheeditor
AT sofenh incidenceofseriousgastrointestinaleventsamongtildrakizumabtreatedpatientswithpsoriasislettertotheeditor
AT mendelsohnam incidenceofseriousgastrointestinaleventsamongtildrakizumabtreatedpatientswithpsoriasislettertotheeditor
AT rozzosj incidenceofseriousgastrointestinaleventsamongtildrakizumabtreatedpatientswithpsoriasislettertotheeditor
AT liq incidenceofseriousgastrointestinaleventsamongtildrakizumabtreatedpatientswithpsoriasislettertotheeditor

Ejemplares similares